• VE-822 ATR Inhibitor: Enhancing DNA Damage Response Research

  2026-04-24

  VE-822 stands out as a potent ATR inhibitor, uniquely enabling selective sensitization of pancreatic cancer cells to chemoradiotherapy. This article bridges cutting-edge reference findings with actionable protocols, troubleshooting guidance, and advanced research applications to optimize DNA damage response studies.

• Danazol (C3644): New Insights into HPG Axis Modulation and A

  2026-04-24

  Explore the multifaceted role of Danazol in HPG axis modulation and advanced assay development. This article uniquely integrates recent animal model findings and technical parameters, offering practical guidance for researchers working with Danazol and related endocrine targets.

• EGCG-Loaded 3D Calcium Phosphate Scaffolds for Bone Repair

  2026-04-23

  This study demonstrates the utility of 3D-printed tricalcium phosphate scaffolds for localized, sustained delivery of (-)-Epigallocatechin gallate (EGCG) to promote osteogenesis and inhibit osteoclastogenesis. The approach provides a multifunctional platform for regenerating craniofacial bone defects after trauma or tumor resection, with distinct advantages over conventional grafts in supporting both bone and vascular tissue formation.

• Laminin (925-933): Protocol Guide for Cell Adhesion & Migrat

  2026-04-23

  Laminin (925-933) is a defined synthetic peptide for reproducible control of cell adhesion, chemotaxis, and migration in basement membrane protein research. It is particularly suited for in vitro assays examining cell behavior, but should not be used for diagnostic or therapeutic purposes.

• IPA-3: Precision Pak1 Autophosphorylation Inhibition in Rese

  2026-04-22

  IPA-3 (1-[(2-hydroxynaphthalen-1-yl)disulfanyl]naphthalen-2-ol) empowers researchers with a non-ATP-competitive mechanism for dissecting Pak1-driven pathways in oncology and neuroinflammation. This guide translates the latest evidence and experimental workflows into actionable steps, highlighting IPA-3's selectivity, troubleshooting insights, and cross-domain relevance.

• pH-Dependent Solubility of LEE011 Succinate: Analytical and

  2026-04-22

  This study presents an analytical Quality by Design (QbD) approach to assess the impact of acid-reducing agents on the solubility and absorption of ribociclib succinate (LEE011 succinate), a selective CDK4/6 inhibitor widely used in cancer research. Results indicate that pH shifts induced by acid-reducing drugs do not significantly affect ribociclib’s solubility or pharmacokinetic profile, supporting its flexible administration in research and clinical settings.

• Rosiglitazone (Brl-49653): Applied Protocols in Metabolic Re

  2026-04-21

  Rosiglitazone (Brl-49653) empowers metabolic research with reproducible PPARγ activation, facilitating advanced studies in adipogenesis, insulin sensitivity, and rare disease rescue. This article translates cutting-edge findings—such as SEMA3E-driven beige adipocyte differentiation—into actionable protocols, troubleshooting guides, and workflow optimizations for experimental success.

• Paclitaxel (Taxol): Cytoskeletal Regulation Beyond Cancer Re

  2026-04-21

  Explore how Paclitaxel (Taxol) enables advanced insights into cytoskeletal dynamics, bridging recent discoveries in tubulin post-translational modifications with next-generation cancer research. Unique practical guidance for protocol design and mechanistic studies.

• Fosinopril Sodium: Precision ACE Inhibition for Translationa

  2026-04-20

  Explore how Fosinopril sodium, a potent ACE inhibitor, enables advanced translational research in hypertension and cardiovascular disease. This article offers a mechanistic deep-dive, unique protocol guidance, and actionable insights for assay design.

• PERK Loss Sensitizes Colorectal Cancer to Ferroptosis via SL

  2026-04-20

  The referenced study demonstrates that loss of PERK function promotes ferroptosis in colorectal cancer by downregulating SLC7A11, a key regulator of cystine import and glutathione synthesis. These findings suggest that targeting the PERK arm of the unfolded protein response could enhance vulnerability of therapy-resistant tumors to ferroptosis, informing new strategies for cancer treatment.

• Chlorpromazine HCl: Dopamine Receptor Antagonist for Researc

  2026-04-19

  Chlorpromazine HCl is a well-characterized dopamine receptor antagonist with broad utility in neuropharmacology and psychotic disorder research. Its mechanism involves potent dopamine receptor inhibition, GABAA receptor modulation, and emerging roles in host-pathogen interaction studies. This dossier details its validated applications, protocol parameters, and limitations with direct evidence links.

• Systematic Evaluation of AKT Inhibitors: Mechanisms and Impl

  2026-04-18

  Kostaras et al. performed a systematic molecular and pharmacologic evaluation of ATP-competitive and allosteric AKT inhibitors, revealing marked drug- and class-specific differences in biological activity. Their work highlights the importance of structural and functional profiling for optimizing the use of AKT inhibitors in cancer research and therapeutic development.

• Aspirin's Role in Limiting Cancer Metastasis via Platelet-T

  2026-04-17

  This study reveals that aspirin impedes cancer metastasis by disrupting platelet-derived thromboxane A2 (TXA2)-mediated suppression of T cell immunity. The findings clarify the immune mechanisms underlying aspirin’s anti-metastatic effect and delineate a novel TXA2–ARHGEF1 pathway as a target for future immunotherapies.

• PP 2 (AG 1879): Precision Src Inhibition in Cell Signaling S

  2026-04-16

  PP 2 (AG 1879) empowers researchers to dissect Src-mediated pathways with high selectivity and reproducible potency, making it a gold-standard tool in cancer biology, immunology, and cytoskeletal signaling research. Explore optimized protocols, advanced troubleshooting, and unique insights from recent studies to maximize experimental reliability.

• Tobramycin: Applied Protocols for Gram-Negative Bacteria Res

  2026-04-15

  Tobramycin, a water-soluble aminoglycoside antibiotic from APExBIO, enables reproducible microbiology workflows targeting Gram-negative bacterial infections. This guide details optimized protocols, troubleshooting strategies, and actionable insights that translate bench evidence into robust experimental outcomes.

15588 records 1/1040 page Next 12345 下5页 Last page